- Home
- ACIC vs ERAS Comparison
ACIC vs ERAS Comparison
Compare ACIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | ERAS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.4M | 4.0B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACIC | ERAS |
|---|---|---|
| Price | $9.18 | $17.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 273.2K | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | 36.23 |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | $11.10 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.20 | $1.33 |
| 52 Week High | $13.06 | $24.28 |
Technical Indicators
Market Signals| Indicator | ACIC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 30.95 | 47.21 |
| Support Level | N/A | $17.36 |
| Resistance Level | $11.48 | $18.20 |
| Average True Range (ATR) | 0.37 | 0.92 |
| MACD | -0.10 | -0.17 |
| Stochastic Oscillator | 3.27 | 33.48 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.